Stocks
Freenome, Inc.FRNM
NASDAQHealthcareBiotechnology$14.06
Price as of · delayed, not real-time
A molecular diagnostics company developing blood-based screening tests for early cancer detection, with a focus on colorectal cancer. Its platform combines cell-free DNA methylation and fragmentomics with machine learning to improve test accuracy. Investors track Freenome for its potential to disrupt the multi-billion-dollar cancer screening market.
52W Range: $9.95-$17.50
Congressional Interest in Freenome, Inc. (FRNM)
No congressional trades have been disclosed for Freenome, Inc. (FRNM) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading FRNM?
No congressional trades found for this stock.